Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 11:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 7,400 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Gastrointestinal Neoplasia Clear all
Completed Phase 2 Interventional

Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment

NCT00091182
View directory record Official record
Conditions
Childhood Central Nervous System Germ Cell Tumor, Childhood Extragonadal Germ Cell Tumor, Childhood Hepatoblastoma, Childhood Hepatocellular Carcinoma, Childhood High-grade Cerebral Astrocytoma, Childhood Low-grade Cerebral Astrocytoma, Childhood Malignant Ovarian Germ Cell Tumor, Childhood Malignant Testicular Germ Cell Tumor, Childhood Teratoma, Recurrent Adrenocortical Carcinoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Liver Cancer, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Childhood Visual Pathway and Hypothalamic Glioma, Recurrent Colon Cancer, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Nasopharyngeal Cancer, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Recurrent Rectal Cancer, Recurrent Renal Cell Cancer
Interventions
oxaliplatin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Sep 22, 2026, 11:08 PM EDT
Completed Phase 1 Interventional

Phase I Study of KRN330 Monoclonal Antibody in Patients With Colorectal Cancer

NCT00575562
View directory record Official record
Conditions
Colorectal Cancer
Interventions
KRN330
Drug
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 28, 2024 · Synced Sep 22, 2026, 11:08 PM EDT
Completed No phase listed Observational

Early Detection of Barrett's Esophagus

NCT00081354
View directory record Official record
Conditions
Barrett's Esophagus
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
737 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 21, 2020 · Synced Sep 22, 2026, 11:08 PM EDT
Completed No phase listed Observational

Evaluating Pancreatic Tumors in Patients With Zollinger-Ellison Syndrome

NCT00001254
View directory record Official record
Conditions
Zollinger Ellison Syndrome
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 100 Years
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1991
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 22, 2026, 11:08 PM EDT
Active, not recruiting Phase 1 Interventional

Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors

NCT07021066
View directory record Official record
Conditions
Gastric Adenocarcinoma, Advanced Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma, Biliary Tract Cancer, Other Solid Tumors
Interventions
BL-M05D1
Drug
Lead sponsor
SystImmune Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
11
States / cities
Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 22, 2026, 11:08 PM EDT
Completed Not applicable Interventional

Daily Imaging, Target Identification, and Simulated Computed Tomography-Based Stereotactic Adaptive Radiotherapy Workflow in a Novel Ring Gantry Radiotherapy Device

NCT04008537
View directory record Official record
Conditions
Cancer of Pancreas, Cancer of Pelvis, Cancer of Abdomen, Cancer of Thorax
Interventions
Ring gantry kV-CBCT combined with linear accelerator
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Sep 22, 2026, 11:08 PM EDT
Terminated Not applicable Interventional

A Trial Comparing Transversus Abdominis Plane Catheter Versus Epidural After Esophagectomy

NCT03570996
View directory record Official record
Conditions
Esophageal Cancer, Pain, Postoperative
Interventions
Esophagectomy, Transversus abdominis plane catheter, Epidural
Procedure
Lead sponsor
Swedish Medical Center
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 22, 2023 · Synced Sep 22, 2026, 11:08 PM EDT
Completed Phase 1 Interventional

Study To Determine The Maximum Range of Light Doses At Two HPPH Doses With Acceptable Normal Tissue Toxicity For PDT Treatment Of High Grade Dysplasia,CIS or Early Adenocarcinoma In Barrett's Esophagus

NCT01238042
View directory record Official record
Conditions
Barrett's Esophagus, CIS, HGD
Interventions
HPPH
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Dec 1, 2014 · Synced Sep 22, 2026, 11:08 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Personal Electronic Health Records in Improving Screening Rates for Colorectal Cancer

NCT01032746
View directory record Official record
Conditions
Colorectal Cancer
Interventions
educational intervention, internet-based intervention, evaluation of cancer risk factors, fecal occult blood test, screening colonoscopy
Other · Procedure
Lead sponsor
Harvard University
Other
Eligibility
50 Years to 75 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2005
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Sep 22, 2026, 11:08 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors

NCT05784688
View directory record Official record
Conditions
Solid Tumor, Biliary Tract Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
Interventions
TU2218 + KEYTRUDA® (Pembrolizumab)
Drug
Lead sponsor
TiumBio Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
3
States / cities
San Antonio, Texas • Tyler, Texas • Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 22, 2026, 11:08 PM EDT
Terminated Phase 1Phase 2 Interventional

A Study of ADH300004 and 5-Fluorouracil in Locally Advanced, Recurrent, or Metastatic Hepatocellular Carcinoma

NCT00319683
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
ADH300004
Drug
Lead sponsor
Adherex Technologies, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Dec 14, 2008 · Synced Sep 22, 2026, 11:08 PM EDT
Completed No phase listed Observational

Risk Factors for Barrett's Esophagus in Patients With BE, Gastroesophageal Reflux, or Gastrointestinal Bleeding

NCT00445653
View directory record Official record
Conditions
Precancerous Condition
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 17, 2017 · Synced Sep 22, 2026, 11:08 PM EDT
Withdrawn No phase listed Observational

Response Assessment by Circulating Tumor DNA in Patients With Locally Advanced Rectal Cancer

NCT04670588
View directory record Official record
Conditions
Rectal Cancer
Interventions
Circulating tumor DNA(ctDNA) level measurement
Diagnostic Test
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 17, 2022 · Synced Sep 22, 2026, 11:08 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Prospective Collection of Samples to Enable the Development of Natera Screening Assay for Early Cancer Detection

NCT06620627
View directory record Official record
Conditions
Colorectal Cancer Screening
Interventions
Not listed
Lead sponsor
Natera, Inc.
Industry
Eligibility
40 Years and older
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Sep 22, 2026, 11:08 PM EDT
Completed Phase 1 Interventional

Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid Tumors

NCT00033241
View directory record Official record
Conditions
Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
erlotinib hydrochloride, gemcitabine hydrochloride
Drug
Lead sponsor
OSI Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
2
States / cities
Tucson, Arizona • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced Sep 22, 2026, 11:08 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

NCT03629756
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Breast Cancer, Colorectal Cancer, Melanoma, Bladder Cancer, Ovarian Cancer, Endometrial Cancer, Merkel Cell Carcinoma, GastroEsophageal Cancer, Renal Cell Carcinoma, Castration-resistant Prostate Cancer
Interventions
Etrumadenant, Zimberelimab
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
12
States / cities
Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Sep 22, 2026, 11:08 PM EDT
Completed No phase listed Observational

The Role of the Fujinon Intelligent Chromo Endoscopy (FICE™) in Barrett's Esophagus

NCT01084629
View directory record Official record
Conditions
Barrett's Esophagus
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Sep 22, 2026, 11:08 PM EDT
Terminated Phase 3 Interventional

A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer

NCT02664077
View directory record Official record
Conditions
Stage III (IIIB or IIIC) Colon Cancer
Interventions
Regorafenib, Placebo
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
51
States / cities
Orange, California • Santa Rosa, California • Vallejo, California + 47 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Sep 22, 2026, 11:08 PM EDT
Withdrawn Not applicable Interventional

Strength for Health

NCT01882972
View directory record Official record
Conditions
Colon Cancer
Interventions
Exercise, Meditation
Behavioral
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Sep 22, 2026, 11:08 PM EDT
Not listed Phase 2 Interventional

Novel Gallium Imaging in Hepatocellular Carcinoma

NCT03116945
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
68Gallium Citrate
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 2, 2019 · Synced Sep 22, 2026, 11:08 PM EDT
Completed Phase 1 Interventional

Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer

NCT02069145
View directory record Official record
Conditions
Hepatocellular Cancer, Liver Cancer
Interventions
OMP-54F28 with Sorafenib
Drug
Lead sponsor
OncoMed Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
6
States / cities
Los Angeles, California • Aurora, Colorado • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Sep 22, 2026, 11:08 PM EDT
Terminated No phase listed Observational

Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer

NCT04561453
View directory record Official record
Conditions
Biliary Tract Cancer, Cholangiocarcinoma, Gallbladder Cancer, Intrahepatic Cholangiocarcinoma, Perihilar Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Hilar Cholangiocarcinoma, Distal Bile Duct Cancer
Interventions
Multi-Platform Profiling with Organoid Drug Sensitivity Screening and ctDNA Monitoring
Diagnostic Test
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Chicago, Illinois • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Sep 22, 2026, 11:08 PM EDT
Completed Not applicable Interventional Results available

Advanced Image Guidance Utilized in Liver Surgery

NCT01666145
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Advanced Image Guidance
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Sep 22, 2026, 11:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer

NCT04670445
View directory record Official record
Conditions
Stage IV Melanoma, Advanced Lung Cancer, Stage IV Non-Small Cell Lung Cancer, Unresectable Non-Small Cell Lung Carcinoma, Unresectable Stage III Non-Small Cell Lung Cancer, Small Cell Lung Cancer Extensive Stage, Stage IV Merkel Cell Carcinoma, Stage IV Cutaneous Squamous Cell Carcinoma, Stage IV Basal Cell Carcinoma, Stage IV Breast Cancer, Stage IV Colorectal Cancer, Stage IV Gastric Cancer, Stage IV Esophageal Cancer, Stage IV Hepatocellular Cancer, Stage IV Renal Cell Carcinoma, Stage IV Bladder Cancer, Stage IV Head and Neck Squamous Cell Carcinoma, Stage IV Cervical Cancer, Stage IV Endometrial Cancer, Stage IV Mesothelioma, Immunotherapy, Immune Checkpoint Inhibitors
Interventions
Educational Video and QPL List, Usual Care
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 22, 2026, 11:08 PM EDT